Abbott Laboratories (ABT) 42.95 $ABT
Australia Peripheral Vascular & Cardiovascular Procedures Devices Market Outlook to 2020 New Report Available at MarketOptimizer.org
PRWeb - Sun Sep 07, 8:30PM CDT
Australia Peripheral Vascular Devices Market Outlook to 2020
Abbott Labs' FreeStyle Libre Flash Glucose Gets CE Mark - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 3:35PM CDT
Abbott Labs (ABT) received positive news when its FreeStyle Libre Flash Glucose Monitoring System obtained CE Mark (Conformite Europeenne) in Europe.
Shares of ABT Up 9.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Sep 05, 11:20AM CDT
SmarTrend identified an Uptrend for Abbott Laboratories (NYSE:ABT) on April 22nd, 2014 at $38.75. In approximately 5 months, Abbott Laboratories has returned 9.85% as of today's recent price of $42.56.
The Zacks Analyst Blog Highlights: Google, AbbVie, Abbott Laboratories, Apple and Intel
PR Newswire - Fri Sep 05, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Google (Nasdaq:GOOGL-Free Report), AbbVie (NYSE:ABBV-Free Report), Abbott Laboratories (NYSE:ABT-Free Report), Apple Inc. (Nasdaq:AAPL-Free Report) and Intel (Nasdaq:INTC-Free Report).
Global Mobile Health and Fitness Sensor Market 2014-2018: Increased Health Awareness Sees Market Set to Grow at a CAGR of 40%
M2 - Fri Sep 05, 8:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mfnjth/global_mobile) has announced the addition of the "Global Mobile Health and Fitness Sensor Market 2014-2018" report to their offering. The Global Mobile Health and Fitness Sensor market to grow at a CAGR of 40.29 percent over the period 2013-2018. A sensor measures physical quantity and converts raw data into observable data, which are used by various industries. Mobile health and fitness sensors are used in health and fitness devices to measure various body parameters. Rapid and continuous development in sensing technology can assist in regular patient monitoring. Going forward, the use of mobile health and fitness sensors in consumer healthcare is expected to boost the Global Mobile Health and Fitness Sensor market. The Global Mobile Health and Fitness Sensor market covers the present scenario and the growth prospects for the period 2014-2018. To calculate market size, the report takes into account the unit shipments of health and fitness sensors used in wearable, implantable, and mobile health and fitness devices. With growing demand from consumers, vendors have started developing multi-functional sensors that can be used to measure different body activities with a single device. The decreasing size of sensors led to a concomitant increase in the demand for implantable sensors. This demand is expected to increase during the forecast period of 2013-2018. According to the report, increased health awareness is a major driver for the Global Mobile Health and Fitness Sensor market. Aging populations and an increased incidence of diseases coupled with higher healthcare costs are some of the concerns and people are becoming increasingly health conscious and are constantly monitoring their body condition to keep fit. Further, the report states that lack of standardization among health and fitness devices remains a major challenge to the growth of the Global Mobile Health and Fitness Sensor market. Key Vendors - Abbott Laboratories - Acute Technology - Bayer HealthCare - F. Hoffmann-La Roche - Fujitsu - GE Healthcare - Honeywell International - LifeScan - Medtronic - OMRON - RF Technologies Other Prominent Vendors - Adidas - AgaMatrix - Analog Devices - Asahi Kasei Microdevices - Bosch Healthcare - Cardiocomm Solutions - Casio - Cellnovo - ChoiceMmed - Covidien - EM Microelectronic - Jawbone - Lifecomm - Philips - Qualcomm - ST Microelectronics - Texas Instruments - Zensorium Market Drivers/Challenges/Trends - Increased Health Awareness - Lack of Standardization - Rapid Growth in Combo Sensors Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by End-users - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/mf...bal_mobile
Abbott Labs' Weakness in Devices Hurts Long-Term Growth Potential
at The Street - Fri Sep 05, 5:00AM CDT
There's no compelling reason to buy this stock above $40.
Google's Calico in $500M Joint Venture with AbbVie - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 3:38PM CDT
Calico, Google's (GOOGL) year-old health startup is collaborating with biotechnology drugmaker, AbbVie, a spin-off from Abbott Laboratories (ABT), for a joint venture to formulate treatments for cancer and Alzheimer's.
Global Companion Diagnostic Technologies Market Opportunities and Forecasts 2013 - 2020
M2 - Thu Sep 04, 10:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3qr68q/global_companion) has announced the addition of the "Global Companion Diagnostic Technologies Market (Indication and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020" report to their offering. The global companion diagnostic market is expected to reach $3.5 billion by 2020, and it would grow at a CAGR of 20% from 2014 to 2020 Companion diagnostics market by indication is segmented into oncology, cardiovascular, CNS, autoimmune & inflammation, virology and others. Presently, majority of the companion diagnostics have been developed for cancer and thus, it is the major revenue generating segment in the overall CD indication market. Companion diagnostics have been developed for breast cancer, lung cancer, colorectal cancer, gastric cancer and melanomas. Companion diagnostics for breast cancer is the highest revenue generator mainly because there has been an increase in the incidences of breast cancer and many companion diagnostics have been developed for detection of the HER/neu biomarker for breast cancer. As of now, companion diagnostics for cardiovascular conditions, central nervous system conditions , inflammation and autoimmune diseases and viral diseases are very few, with a majority still in development stage; however, as more and more biomarkers are being discovered, there would be an increase in development of new companion diagnostics. Companion diagnostics market by technology is segmented into immmunohistochemistry and molecular diagnostics. Molecular diagnostics has been the most favored technology and it is expected that next generation sequencing and real-time PCR would drive the growth of this market owing to recent advancements in these technologies. KEY DELIVERABLES MARKET BY INDICATIONS - Oncology - Cardiovascular - Central Nervous System - Auto immune & Inflammation - Virology - Others MARKET BY TECHNOLOGY - Immunohistochemistry - Molecular diagnostics - In situ Hybridization - FISH - CISH - Real time PCR - Gene Sequencing COMPANY PROFILES - Abbott Laboratories - bioMerieux - Dako (Agilent Technologies) - Leica Microsystems - Life Technologies - Myriad Genetics - Qiagen - Resonance Health Ltd - Roche - Ventana Medical Systems For more information visit http://www.researchandmarkets.com/research/3q..._companion
RBCC Explores Novel Uses for New Naltrexone Delivery Protocols
Business Wire - Thu Sep 04, 4:00AM CDT
From chronic pain to obesity, new research suggests that there are practically no limits to the number of illnesses that the prescription drug Naltrexone can treat. Biotech company Rainbow Coral Corp. (OTCBB:RBCC) is working to make Naltrexone more effective than ever before.
Abbott Laboratories Rises 1.26% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Sep 03, 3:57PM CDT
Abbott Laboratories (NYSE:ABT) traded in a range yesterday that spanned from a low of $42.35 to a high of $42.79. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $42.60 on volume of 4.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
FDA: Little evidence to support testosterone drugs
By MATTHEW PERRONE - AP - Wed Sep 03, 2:18PM CDT
WASHINGTON (AP) — The Food and Drug Administration says there is little evidence that testosterone-boosting drugs taken by millions of American men are beneficial, though the agency is also unconvinced by studies suggesting the hormone carries serious risks.
Google's health startup forges venture with AbbVie
AP - Wed Sep 03, 1:09PM CDT
SAN FRANCISCO (AP) — Google's ambitious health startup is teaming up with biotechnology drugmaker AbbVie in a $500 million joint venture that will try to develop new ways to treat cancer and other diseases such as Alzheimer's.
Global Heart Valve Repair and Replacement Market 2014-2018 - Key Vendors are Abbott Laboratories, Edward Lifesciences, Medtronic & St. Jude Medical
M2 - Wed Sep 03, 8:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4bq7ck/global_heart) has announced the addition of the "Global Heart Valve Repair and Replacement Market 2014-2018" report to their offering. The Global Heart Valve Repair and Replacement market to grow at a CAGR of 7.72 percent over the period 2013-2018. Heart valves are structures in the human heart which control the flow of blood during the cardiac cycle. A person affected with heart valve diseases such as valvular stenosis, valvular insufficiency or regurgitation, prolapse, and atresia requires the repair or replacement of the natural heart valves. Aortic valves cannot be repaired; therefore, it is replaced using prosthetic heart valves. However, the mitral, tricuspid, and pulmonary valves can be repaired as well as replaced depending on the diseased condition and functionality of these valves. Heart valve repair and replacement devices are used for repairing the diseased heart valves as well as for replacing the natural valves with prosthetic valves. One of the emerging trends in the market is the increase in the number of products approved by regulatory authorities such as the FDA and CE. Such products are considered to be safe for commercial use increasing their adoption rate. According to the report, the increase in the aging population is one of the major drivers in the market. The incidence of cardiac disorders is more prevalent among the aging population across the world and people above the age of 60 years affected by heart valve diseases is expected to contribute to the growth the market. Further, the report states that the potential risk of complications associated with the use of heart valve repair and replacement devices is proving to be a barrier to the adoption of these devices. Some of the complications are device migration, infection, thrombosis, and mortality. In terms of application, the Global Heart Valve Repair and Replacement market can be segmented into two: - Heart Valve Repair - Heart Valve Replacement Key Questions Answered in this Report - What will the market size be in 2018 and what will the growth rate be? - What are the Key Market Trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors? Key Vendors - Abbott Laboratories - Edward Lifesciences - Medtronic - St. Jude Medical Other Prominent Vendors - AorTech - Boston Scientific - Colibri Heart Valve - CryoLife - Direct Flow Medical - JenaValve - MiCardia - Mitralign - Neovasc - On-X Life Technologies - Sorin - Symentis - ValveXchange For more information visit http://www.researchandmarkets.com/research/4b...obal_heart
Abbott Receives CE Mark for FreeStyle® Libre, a Revolutionary Glucose Monitoring System for People with Diabetes
PR Newswire - Wed Sep 03, 8:30AM CDT
Abbott (NYSE: ABT) today announced that it has received CE Mark (Conformite Europeenne) for its FreeStyle® Libre Flash Glucose Monitoring System, a revolutionary new glucose sensing technology for people with diabetes. The system eliminates the need for routine finger pricks1, reading glucose levels through a sensor that can be worn on the back of the upper arm for up to 14 days. In addition, no finger prick calibration is needed--a key differentiator from current continuous glucose monitoring systems. The system will be available in seven countries across Europe in the coming weeks.
Favourable Rulings, Upcoming Conferences, Clinical Study Results, Drug Availability, and Tender Offers - Research Reports on United Therapeutics, Illumina, AstraZeneca, Eli Lilly and Abbott
PR Newswire - Wed Sep 03, 8:20AM CDT
Today, Analysts Review released its research reports regarding United Therapeutics Corporation (NASDAQ: UTHR), Illumina, Inc. (NASDAQ: ILMN), AstraZeneca plc (NYSE: AZN), Eli Lilly and Co. (NYSE: LLY) and Abbott Laboratories (NYSE: ABT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6174-100free.
LABS, Inc. Names Todd G. Johnson as President and Chief Executive Officer
Business Wire - Tue Sep 02, 2:57PM CDT
LABS, Inc., a Centennial-based comprehensive, highly accredited specialized clinical reference testing laboratory, announced it has appointed Todd G. Johnson, MBA, as President and Chief Executive Officer. Based at LABS, Inc. Centennial headquarters, Johnson's initial priorities will be to continue to grow the company, and ensure that the organization remains competitive within the market place.
Next Support Level for Abbott Laboratories (ABT) is $41.89
Comtex SmarTrend(R) - Tue Sep 02, 12:28PM CDT
Shares of Abbott Laboratories (NYSE:ABT) opened today below their pivot of $42.24 and have already reached the first level of support at $42.06. Analysts will be watching for a cross of the next downside pivot targets of $41.89 and $41.54.
Fitch Maintains CFR's IDRs on Rating Watch Positive
Business Wire - Fri Aug 29, 12:47PM CDT
Fitch Ratings maintains CFR Pharmaceuticals S.A. and its subsidiary CFR International SpA on Rating Watch Positive in anticipation of their acquisition by Abbott Investments Luxembourg S.A.R.L., a subsidiary of Abbott Laboratories (Abbott; rated 'A+' by Fitch). A complete list of rating actions follows at the end of this press release.
Drug Discovery Technologies - A Global Market Overview
M2 - Fri Aug 29, 5:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dtdx3f/drug_discovery) has announced the addition of the "Drug Discovery Technologies - A Global Market Overview" report to their offering. The development of new drugs for treating difficult diseases, such as cancer requires extensive expenditure, in addition to consuming a lot of time. The first step in designing a new drug involves the utilizing high-throughput screening of large chemical libraries for identifying compounds that can provide the requisite therapeutic effect. The capability of visualizing biological activity at the cellular level has constituted a strategic component in drug discovery, and adding automation and high-volume screening methods has enabled in testing compounds in large numbers. The field of pharmaceutical research is being provided considerable impetus through the combination of imaging and screening. Key Topics Covered: PART A: GLOBAL MARKET PERSPECTIVE 1. INTRODUCTION 2. KEY MARKET TRENDS 3. RECENT PATENTS IN DRUG DISCOVERY LANDSCAPE 4. KEY GLOBAL PLAYERS 5. KEY BUSINESS TRENDS 6. GLOBAL MARKET OVERVIEW PART B: REGIONAL MARKET PERSPECTIVE 1. THE UNITED STATES 2. EUROPE 3. ASIA-PACIFIC 4. REST OF WORLD PART C: GUIDE TO THE INDUSTRY 1. NORTH AMERICA 2. EUROPE 3. ASIA-PACIFIC 4. REST OF WORLD PART
ANNEXURE 1. RESEARCH METHOLOGY 2. FEEDBACK Companies Mentioned: - 4-Antibody AG - Abbott Laboratories - Accelrys, Inc. - Affymetrix Inc. - Agilent Technologies Inc. - Asahi Kasei Pharma Corporation - Astrazeneca Plc - Aviva Biosciences Corp. - Bayer Healthcare AG - BD Biosciences - Beckman Coulter Inc. - Biacore International AB - Bioanalytical Systems, Inc. - Bio-Rad Laboratories, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Caliper Life Sciences, Inc. - Caprion Proteomics, Inc. - Celera Corporation - Celgene Corporation - Charles River Laboratories International, Inc. - Compugen Ltd. - Decode Genetics, Inc. - EMD Millipore Corporation - Evotec AG - GE Healthcare Ltd. - Genedata AG - Hitgen Ltd - Hudson Robotics, Inc. - Illumina Inc. - Incyte Corporation - Isis Pharmaceuticals, Inc. - Kyowa Hakko Kirin Co., Ltd. - Luminex Corporation - Maxcyte, Inc - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Molecular Devices, LLC - Molecular Discovery Ltd. - Molecular Discovery Systems Pty., Ltd. - New England Biolabs, Inc. - Novartis AG - Osiris Therapeutics Inc. - Perkinelmer, Inc. - Promega Corporation - Qiagen N.V. - Quantum Pharmaceuticals - Roche Holding AG - Shimadzu Corporation - Sigma-Aldrich Corporation - Sri Biosciences - Tecan Group Ltd. - The National Center for Drug Screening - Thermo Fisher Scientific Inc. - Viva Biotech Ltd - Waters Corp. For more information visit http://www.researchandmarkets.com/research/dt..._discovery
Global Infant Formula Market Report: Focus on China 2014
M2 - Thu Aug 28, 9:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/twqn7f/global_infant) has announced the addition of the "Global Infant Formula Market Report: Focus on China" report to their offering. The market for infant formula products is one of the major and the fastest growing segments of the overall baby foods industry. Infant formula is either a partial or a total substitute for breast milk for infants and is recommended for feeding during the first twelve months. Since the start of the millennium, international awareness regarding the importance of early childhood nutrition has been on the rise. All over the world parents are becoming more concerned about the nutritional benefit of pediatric foods and breast-milk supplements. Increasing proportion of women participation in labor force and increased affordability supported by waning price responsiveness and a rise in disposable income across the world are the major factors that have helped the global IMF market to attain stronger growth levels. Though the market has been experiencing lower demand and growth from the traditional matured markets of the West stemming primarily from declining birth rate, the developing world, especially the Asia and Pacific region and Latin America have provided the headroom for the global market expansion. The market is dominated by the Asian region which consumes about three-fifths of the global IMF supplies. Particularly, China has gained the stature to maneuver the market single-handedly since the country alone accounts for about two-fifth of the global IMF market revenues. The report, Global Infant Formula Market prudently analyzes the development of the respective market, with a focus on the single largest market, China, and other regional but important markets. The report discusses the major trends, growth drivers as well as issues being faced by the industry. The global infant formula market is predominated by a handful of players including Nestl?, Danone, Mead Johnson Nutrition and Abbott which keep vying for greater market share. The profiles of these leading players are also included in the report along with their key financials and strategies for growth. . Key Topics Covered: 1. Market Overview 2. Baby Food/Infant Nutrition Market 3. Market Dynamics 4. Competitive Landscape 5. Company Profiles 6. Market Outlook Companies Mentioned - Abbott Laboratories - Danone S.A. - Mead Johnson Nutrition Co. - Nestl? S.A. For more information visit http://www.researchandmarkets.com/research/tw...bal_infant
Australia Peripheral Vascular & Cardiovascular Procedures Devices Market Outlook to 2020 New Report Available at MarketOptimizer.org
PRWeb - Sun Sep 07, 8:30PM CDT
Australia Peripheral Vascular Devices Market Outlook to 2020
Abbott Labs' FreeStyle Libre Flash Glucose Gets CE Mark - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 3:35PM CDT
Abbott Labs (ABT) received positive news when its FreeStyle Libre Flash Glucose Monitoring System obtained CE Mark (Conformite Europeenne) in Europe.
Shares of ABT Up 9.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Sep 05, 11:20AM CDT
SmarTrend identified an Uptrend for Abbott Laboratories (NYSE:ABT) on April 22nd, 2014 at $38.75. In approximately 5 months, Abbott Laboratories has returned 9.85% as of today's recent price of $42.56.
The Zacks Analyst Blog Highlights: Google, AbbVie, Abbott Laboratories, Apple and Intel
PR Newswire - Fri Sep 05, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Google (Nasdaq:GOOGL-Free Report), AbbVie (NYSE:ABBV-Free Report), Abbott Laboratories (NYSE:ABT-Free Report), Apple Inc. (Nasdaq:AAPL-Free Report) and Intel (Nasdaq:INTC-Free Report).
Global Mobile Health and Fitness Sensor Market 2014-2018: Increased Health Awareness Sees Market Set to Grow at a CAGR of 40%
M2 - Fri Sep 05, 8:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mfnjth/global_mobile) has announced the addition of the "Global Mobile Health and Fitness Sensor Market 2014-2018" report to their offering. The Global Mobile Health and Fitness Sensor market to grow at a CAGR of 40.29 percent over the period 2013-2018. A sensor measures physical quantity and converts raw data into observable data, which are used by various industries. Mobile health and fitness sensors are used in health and fitness devices to measure various body parameters. Rapid and continuous development in sensing technology can assist in regular patient monitoring. Going forward, the use of mobile health and fitness sensors in consumer healthcare is expected to boost the Global Mobile Health and Fitness Sensor market. The Global Mobile Health and Fitness Sensor market covers the present scenario and the growth prospects for the period 2014-2018. To calculate market size, the report takes into account the unit shipments of health and fitness sensors used in wearable, implantable, and mobile health and fitness devices. With growing demand from consumers, vendors have started developing multi-functional sensors that can be used to measure different body activities with a single device. The decreasing size of sensors led to a concomitant increase in the demand for implantable sensors. This demand is expected to increase during the forecast period of 2013-2018. According to the report, increased health awareness is a major driver for the Global Mobile Health and Fitness Sensor market. Aging populations and an increased incidence of diseases coupled with higher healthcare costs are some of the concerns and people are becoming increasingly health conscious and are constantly monitoring their body condition to keep fit. Further, the report states that lack of standardization among health and fitness devices remains a major challenge to the growth of the Global Mobile Health and Fitness Sensor market. Key Vendors - Abbott Laboratories - Acute Technology - Bayer HealthCare - F. Hoffmann-La Roche - Fujitsu - GE Healthcare - Honeywell International - LifeScan - Medtronic - OMRON - RF Technologies Other Prominent Vendors - Adidas - AgaMatrix - Analog Devices - Asahi Kasei Microdevices - Bosch Healthcare - Cardiocomm Solutions - Casio - Cellnovo - ChoiceMmed - Covidien - EM Microelectronic - Jawbone - Lifecomm - Philips - Qualcomm - ST Microelectronics - Texas Instruments - Zensorium Market Drivers/Challenges/Trends - Increased Health Awareness - Lack of Standardization - Rapid Growth in Combo Sensors Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by End-users - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/mf...bal_mobile
Abbott Labs' Weakness in Devices Hurts Long-Term Growth Potential
at The Street - Fri Sep 05, 5:00AM CDT
There's no compelling reason to buy this stock above $40.
Google's Calico in $500M Joint Venture with AbbVie - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 3:38PM CDT
Calico, Google's (GOOGL) year-old health startup is collaborating with biotechnology drugmaker, AbbVie, a spin-off from Abbott Laboratories (ABT), for a joint venture to formulate treatments for cancer and Alzheimer's.
Global Companion Diagnostic Technologies Market Opportunities and Forecasts 2013 - 2020
M2 - Thu Sep 04, 10:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3qr68q/global_companion) has announced the addition of the "Global Companion Diagnostic Technologies Market (Indication and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020" report to their offering. The global companion diagnostic market is expected to reach $3.5 billion by 2020, and it would grow at a CAGR of 20% from 2014 to 2020 Companion diagnostics market by indication is segmented into oncology, cardiovascular, CNS, autoimmune & inflammation, virology and others. Presently, majority of the companion diagnostics have been developed for cancer and thus, it is the major revenue generating segment in the overall CD indication market. Companion diagnostics have been developed for breast cancer, lung cancer, colorectal cancer, gastric cancer and melanomas. Companion diagnostics for breast cancer is the highest revenue generator mainly because there has been an increase in the incidences of breast cancer and many companion diagnostics have been developed for detection of the HER/neu biomarker for breast cancer. As of now, companion diagnostics for cardiovascular conditions, central nervous system conditions , inflammation and autoimmune diseases and viral diseases are very few, with a majority still in development stage; however, as more and more biomarkers are being discovered, there would be an increase in development of new companion diagnostics. Companion diagnostics market by technology is segmented into immmunohistochemistry and molecular diagnostics. Molecular diagnostics has been the most favored technology and it is expected that next generation sequencing and real-time PCR would drive the growth of this market owing to recent advancements in these technologies. KEY DELIVERABLES MARKET BY INDICATIONS - Oncology - Cardiovascular - Central Nervous System - Auto immune & Inflammation - Virology - Others MARKET BY TECHNOLOGY - Immunohistochemistry - Molecular diagnostics - In situ Hybridization - FISH - CISH - Real time PCR - Gene Sequencing COMPANY PROFILES - Abbott Laboratories - bioMerieux - Dako (Agilent Technologies) - Leica Microsystems - Life Technologies - Myriad Genetics - Qiagen - Resonance Health Ltd - Roche - Ventana Medical Systems For more information visit http://www.researchandmarkets.com/research/3q..._companion
RBCC Explores Novel Uses for New Naltrexone Delivery Protocols
Business Wire - Thu Sep 04, 4:00AM CDT
From chronic pain to obesity, new research suggests that there are practically no limits to the number of illnesses that the prescription drug Naltrexone can treat. Biotech company Rainbow Coral Corp. (OTCBB:RBCC) is working to make Naltrexone more effective than ever before.
Abbott Laboratories Rises 1.26% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Sep 03, 3:57PM CDT
Abbott Laboratories (NYSE:ABT) traded in a range yesterday that spanned from a low of $42.35 to a high of $42.79. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $42.60 on volume of 4.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
FDA: Little evidence to support testosterone drugs
By MATTHEW PERRONE - AP - Wed Sep 03, 2:18PM CDT
WASHINGTON (AP) — The Food and Drug Administration says there is little evidence that testosterone-boosting drugs taken by millions of American men are beneficial, though the agency is also unconvinced by studies suggesting the hormone carries serious risks.
Google's health startup forges venture with AbbVie
AP - Wed Sep 03, 1:09PM CDT
SAN FRANCISCO (AP) — Google's ambitious health startup is teaming up with biotechnology drugmaker AbbVie in a $500 million joint venture that will try to develop new ways to treat cancer and other diseases such as Alzheimer's.
Global Heart Valve Repair and Replacement Market 2014-2018 - Key Vendors are Abbott Laboratories, Edward Lifesciences, Medtronic & St. Jude Medical
M2 - Wed Sep 03, 8:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4bq7ck/global_heart) has announced the addition of the "Global Heart Valve Repair and Replacement Market 2014-2018" report to their offering. The Global Heart Valve Repair and Replacement market to grow at a CAGR of 7.72 percent over the period 2013-2018. Heart valves are structures in the human heart which control the flow of blood during the cardiac cycle. A person affected with heart valve diseases such as valvular stenosis, valvular insufficiency or regurgitation, prolapse, and atresia requires the repair or replacement of the natural heart valves. Aortic valves cannot be repaired; therefore, it is replaced using prosthetic heart valves. However, the mitral, tricuspid, and pulmonary valves can be repaired as well as replaced depending on the diseased condition and functionality of these valves. Heart valve repair and replacement devices are used for repairing the diseased heart valves as well as for replacing the natural valves with prosthetic valves. One of the emerging trends in the market is the increase in the number of products approved by regulatory authorities such as the FDA and CE. Such products are considered to be safe for commercial use increasing their adoption rate. According to the report, the increase in the aging population is one of the major drivers in the market. The incidence of cardiac disorders is more prevalent among the aging population across the world and people above the age of 60 years affected by heart valve diseases is expected to contribute to the growth the market. Further, the report states that the potential risk of complications associated with the use of heart valve repair and replacement devices is proving to be a barrier to the adoption of these devices. Some of the complications are device migration, infection, thrombosis, and mortality. In terms of application, the Global Heart Valve Repair and Replacement market can be segmented into two: - Heart Valve Repair - Heart Valve Replacement Key Questions Answered in this Report - What will the market size be in 2018 and what will the growth rate be? - What are the Key Market Trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors? Key Vendors - Abbott Laboratories - Edward Lifesciences - Medtronic - St. Jude Medical Other Prominent Vendors - AorTech - Boston Scientific - Colibri Heart Valve - CryoLife - Direct Flow Medical - JenaValve - MiCardia - Mitralign - Neovasc - On-X Life Technologies - Sorin - Symentis - ValveXchange For more information visit http://www.researchandmarkets.com/research/4b...obal_heart
Abbott Receives CE Mark for FreeStyle® Libre, a Revolutionary Glucose Monitoring System for People with Diabetes
PR Newswire - Wed Sep 03, 8:30AM CDT
Abbott (NYSE: ABT) today announced that it has received CE Mark (Conformite Europeenne) for its FreeStyle® Libre Flash Glucose Monitoring System, a revolutionary new glucose sensing technology for people with diabetes. The system eliminates the need for routine finger pricks1, reading glucose levels through a sensor that can be worn on the back of the upper arm for up to 14 days. In addition, no finger prick calibration is needed--a key differentiator from current continuous glucose monitoring systems. The system will be available in seven countries across Europe in the coming weeks.
Favourable Rulings, Upcoming Conferences, Clinical Study Results, Drug Availability, and Tender Offers - Research Reports on United Therapeutics, Illumina, AstraZeneca, Eli Lilly and Abbott
PR Newswire - Wed Sep 03, 8:20AM CDT
Today, Analysts Review released its research reports regarding United Therapeutics Corporation (NASDAQ: UTHR), Illumina, Inc. (NASDAQ: ILMN), AstraZeneca plc (NYSE: AZN), Eli Lilly and Co. (NYSE: LLY) and Abbott Laboratories (NYSE: ABT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6174-100free.
LABS, Inc. Names Todd G. Johnson as President and Chief Executive Officer
Business Wire - Tue Sep 02, 2:57PM CDT
LABS, Inc., a Centennial-based comprehensive, highly accredited specialized clinical reference testing laboratory, announced it has appointed Todd G. Johnson, MBA, as President and Chief Executive Officer. Based at LABS, Inc. Centennial headquarters, Johnson's initial priorities will be to continue to grow the company, and ensure that the organization remains competitive within the market place.
Next Support Level for Abbott Laboratories (ABT) is $41.89
Comtex SmarTrend(R) - Tue Sep 02, 12:28PM CDT
Shares of Abbott Laboratories (NYSE:ABT) opened today below their pivot of $42.24 and have already reached the first level of support at $42.06. Analysts will be watching for a cross of the next downside pivot targets of $41.89 and $41.54.
Fitch Maintains CFR's IDRs on Rating Watch Positive
Business Wire - Fri Aug 29, 12:47PM CDT
Fitch Ratings maintains CFR Pharmaceuticals S.A. and its subsidiary CFR International SpA on Rating Watch Positive in anticipation of their acquisition by Abbott Investments Luxembourg S.A.R.L., a subsidiary of Abbott Laboratories (Abbott; rated 'A+' by Fitch). A complete list of rating actions follows at the end of this press release.
Drug Discovery Technologies - A Global Market Overview
M2 - Fri Aug 29, 5:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dtdx3f/drug_discovery) has announced the addition of the "Drug Discovery Technologies - A Global Market Overview" report to their offering. The development of new drugs for treating difficult diseases, such as cancer requires extensive expenditure, in addition to consuming a lot of time. The first step in designing a new drug involves the utilizing high-throughput screening of large chemical libraries for identifying compounds that can provide the requisite therapeutic effect. The capability of visualizing biological activity at the cellular level has constituted a strategic component in drug discovery, and adding automation and high-volume screening methods has enabled in testing compounds in large numbers. The field of pharmaceutical research is being provided considerable impetus through the combination of imaging and screening. Key Topics Covered: PART A: GLOBAL MARKET PERSPECTIVE 1. INTRODUCTION 2. KEY MARKET TRENDS 3. RECENT PATENTS IN DRUG DISCOVERY LANDSCAPE 4. KEY GLOBAL PLAYERS 5. KEY BUSINESS TRENDS 6. GLOBAL MARKET OVERVIEW PART B: REGIONAL MARKET PERSPECTIVE 1. THE UNITED STATES 2. EUROPE 3. ASIA-PACIFIC 4. REST OF WORLD PART C: GUIDE TO THE INDUSTRY 1. NORTH AMERICA 2. EUROPE 3. ASIA-PACIFIC 4. REST OF WORLD PART
ANNEXURE 1. RESEARCH METHOLOGY 2. FEEDBACK Companies Mentioned: - 4-Antibody AG - Abbott Laboratories - Accelrys, Inc. - Affymetrix Inc. - Agilent Technologies Inc. - Asahi Kasei Pharma Corporation - Astrazeneca Plc - Aviva Biosciences Corp. - Bayer Healthcare AG - BD Biosciences - Beckman Coulter Inc. - Biacore International AB - Bioanalytical Systems, Inc. - Bio-Rad Laboratories, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Caliper Life Sciences, Inc. - Caprion Proteomics, Inc. - Celera Corporation - Celgene Corporation - Charles River Laboratories International, Inc. - Compugen Ltd. - Decode Genetics, Inc. - EMD Millipore Corporation - Evotec AG - GE Healthcare Ltd. - Genedata AG - Hitgen Ltd - Hudson Robotics, Inc. - Illumina Inc. - Incyte Corporation - Isis Pharmaceuticals, Inc. - Kyowa Hakko Kirin Co., Ltd. - Luminex Corporation - Maxcyte, Inc - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Molecular Devices, LLC - Molecular Discovery Ltd. - Molecular Discovery Systems Pty., Ltd. - New England Biolabs, Inc. - Novartis AG - Osiris Therapeutics Inc. - Perkinelmer, Inc. - Promega Corporation - Qiagen N.V. - Quantum Pharmaceuticals - Roche Holding AG - Shimadzu Corporation - Sigma-Aldrich Corporation - Sri Biosciences - Tecan Group Ltd. - The National Center for Drug Screening - Thermo Fisher Scientific Inc. - Viva Biotech Ltd - Waters Corp. For more information visit http://www.researchandmarkets.com/research/dt..._discovery Global Infant Formula Market Report: Focus on China 2014
M2 - Thu Aug 28, 9:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/twqn7f/global_infant) has announced the addition of the "Global Infant Formula Market Report: Focus on China" report to their offering. The market for infant formula products is one of the major and the fastest growing segments of the overall baby foods industry. Infant formula is either a partial or a total substitute for breast milk for infants and is recommended for feeding during the first twelve months. Since the start of the millennium, international awareness regarding the importance of early childhood nutrition has been on the rise. All over the world parents are becoming more concerned about the nutritional benefit of pediatric foods and breast-milk supplements. Increasing proportion of women participation in labor force and increased affordability supported by waning price responsiveness and a rise in disposable income across the world are the major factors that have helped the global IMF market to attain stronger growth levels. Though the market has been experiencing lower demand and growth from the traditional matured markets of the West stemming primarily from declining birth rate, the developing world, especially the Asia and Pacific region and Latin America have provided the headroom for the global market expansion. The market is dominated by the Asian region which consumes about three-fifths of the global IMF supplies. Particularly, China has gained the stature to maneuver the market single-handedly since the country alone accounts for about two-fifth of the global IMF market revenues. The report, Global Infant Formula Market prudently analyzes the development of the respective market, with a focus on the single largest market, China, and other regional but important markets. The report discusses the major trends, growth drivers as well as issues being faced by the industry. The global infant formula market is predominated by a handful of players including Nestl?, Danone, Mead Johnson Nutrition and Abbott which keep vying for greater market share. The profiles of these leading players are also included in the report along with their key financials and strategies for growth. . Key Topics Covered: 1. Market Overview 2. Baby Food/Infant Nutrition Market 3. Market Dynamics 4. Competitive Landscape 5. Company Profiles 6. Market Outlook Companies Mentioned - Abbott Laboratories - Danone S.A. - Mead Johnson Nutrition Co. - Nestl? S.A. For more information visit http://www.researchandmarkets.com/research/tw...bal_infant
